AzTrials
AzTrials

HypercholesterolemiaNCT05082350

Nutritional Intervention With Black Garlic

A study testing black garlic in people with Hypercholesterolemia and Hypertension, run by Maria Pilar Zafrilla Rentero at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Read more about this study

Who is it for?
Ages 40 to 65 yearsHealthy volunteers can take part
What is being tested?
black garlic
Could I receive a placebo?
No, everyone receives an active treatment
How many people
62 participants
Where
1 siteSpain
Study dates
1 Sep 2020to 30 Nov 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy Group:
  • Total blood cholesterol levels of less than 200 mg/dL
  • LDL-cholesterol levels of less than 135 mg/dL
  • Not suffer from any other pathology.
  • No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.
  • Cardiovascular Risk Group:
Show all 10Show fewer
  • Total cholesterol levels between 200-300 mg/dL
  • LDL-cholesterol levels between 135-175 mg/dL.
  • No acute or chronic pathology, except hypercholesterolemia
  • No drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism, etc.).

Who cannot join

  • Failure to meet any of the inclusion criteria

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Universidad Católica de Murcia (UCAM)

    Murcia, 30107

Other trials in Spain

About this study

Official title: Clinical Trial to Evaluate the Efficacy of Black Garlic in Reducing Cardiovascular Risk in Subjects With Hypercholesterolemia

A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease. Black garlic is the result of a fermentation process of common white garlic in which the temperature and humidity are kept constant over a long period of time. Black garlic is particularly rich in phenolic compounds such as S-allylcysteine or S-allyl-mercaptocysteine, with antioxidant action. It also provides vitamin C and other valuable antioxidant substances such as flavonoids.

Read the detailed description

A parallel, controlled clinical trial will be performed to assess the effect of garlic on mild hypercholesterolemia.

The study will conducted in two groups of volunteer: healthy and at cardiovascular risk (hypercholesterolemic subjects), consuming black garlic, with each individual acting as its own control. The study will have a total duration of 18 weeks, divided in two stages:

  • Stage 1: basal or washout stage of 2 weeks, in which volunteer follow their usual diet with restrictions
  • Stage 2: intervention stage of 16 weeks, in which volunteer consume black garlic Sixty healthy volunteers (men and women) between 40-65 years old and BMI between 24.9-29.9 kg/m2 will be recruited. From the total of volunteer, 30 will correspond to the Healthy Group, which should have total blood cholesterol levels less than 200 mg/dL and LDL-cholesterol less than 135 mg/dL.

The other 30 volunteers correspond to the Cardiovascular Risk Group, which should have total cholesterol levels between 200-300 mg/dL and LDL-cholesterol levels between 135-175 mg/dL.

Other inclusion criteria established for all volunteers are: no acute or chronic pathology, (except hypercholesterolemia for the risk group), no taking drugs, hormones or dietary supplements, no smoking, no pregnancy, no vegetarianism.

The study has been approved by the Ethical Committee of Catholic University of Murcia (UCAM) and will be carried out in accordance with the Helsinki Declaration of Human Studies. Recruitment will take place at various Health Centers and at UCAM. All participants will be informed on the characteristics of the study and, after signing the informed consent, a routine analysis will be requested to classify the volunteer in the healthy or cardiovascular risk group.

To avoid bias due to gender, the number of women and men recruited in both groups will be balanced. The size of the study population has been estimated taking total blood cholesterol level as the main variable and taking into account that the study design is randomized and parallel. Considering a statistical power of 80%, a statistical significance level of 5% (one tail), a standard deviation of 6.5, aiming to estimate a difference of 2.5, the number of volunteers required is 25 for each group, rising to 30 in anticipation of dropouts. This number, being two study groups, will allow obtaining results with statistical significance in other biochemical parameters that would be determined as secondary variables of the study and that would inform on the effect of black garlic consumption on cardiovascular function and associated dysfunctions (inflammation, hypertension, endothelial function, diabetes, etc.).

After an initial washout (basal) stage common to all groups, in which the volunteers will consume their usual diet with restriction in the consumption of fresh garlic and garlic products, the intervention will start, with the consumption of black garlic for 12 weeks. Volunteers will be provided with black garlic and they will ensure that no other type of garlic or culinary seasoning is used.

Dietary and physical activity questionnaire according to the "Global Physical Activity Questionnarie (GPAQ)" will be compiled in order to collect information on habits and lifestyle, as well as to ensure the compliance of food restrictions.

During the study, visits will be scheduled on the first day and last day of each stage. The subjects will come to the Unit on fasting conditions and will provide the first morning urine. Blood sample will be taken, plasma aliquoted and stored at -80°C until analysis.

Being tested
black garlic
Keywords
black garlic, sulphur bioactive compounds, hypercholesterolemia, hyperlipemia, inflammation, endothelial dysfunction
Medical subject headings
Hypercholesterolemia, Hypertension, Hyperlipidemias, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • black garlicDietary supplement

    Daily consumption of 4 cloves of black garlic, not cooked, during 12 weeks

Study groups in NCT05082350
Study groupRoleWhat they receive
Healthy Group,ExperimentalDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Receives: Dietary Supplement: black garlic
HypercholesterolemiaExperimentalDaily consumption of 4 cloves of black garlic, not cooked, during 12 weeks
Receives: Dietary Supplement: black garlic

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Impact on blood pressure

    Blood pressure (diastolic, systolic)

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  2. Impact on lipid profile

    Plasma levels of total cholesterol, HDL, LDL, VLDL (very low-density lipoprotein), triglycerides, apolipoproteins A1 and B.

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

Secondary outcomes (9)
  1. Impact on blood cells (Hematology)

    Blood counts

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  2. evaluation of liver function to determine product safety

    Hepatic enzymes (GOT, GPT)

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  3. Changes in cytokine levels

    Plasma levels of pro-inflammatory: IL-1β, IL6 , TNF-α (tumor necrosis factor) and anti-inflammatory (IL-10, IL-17) cytokines.

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  4. Changes in chemokine MCP-1 (monocyte chemotactic protein)

    Plasma levels of chemokine MCP-1

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  5. Changes in C reactive protein

    Plasma levels of C reactive protein

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  6. Impact on endothelial function

    Plasma levels of nitric oxide, adhesion molecules VCAM-1 (vascular endothelial cell adhesion molecule), ICAM-1 (intercellular adhesion molecule), chemokines as markers of endothelium (E-selectin) and platelet (P-selectin) activation.

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  7. Impact on glucose levels

    Plasma levels of glucose

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  8. Impact on glycosylated hemoglobin (HbA1c)

    Plasma levels of glycosylated hemoglobin

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

  9. Impact in hormones related to metabolism

    Plasma levels of thyroid hormones (TSH, T3, T4).

    Measured: changes observed from baseline at day 0 compared to 12 weeks.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Oct 2021
  2. Study start1 Sep 2020
  3. Primary completion30 Jun 2021
  4. Study completion30 Nov 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
A controlled clinical intervention study is proposed to determine the effect of black garlic consumption on biomarkers of cardiovascular function and associated pathologies in a healthy population at risk for cardiovascular disease.
Masking
None (open label)
Enrolment
62 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05082350
Sponsor's protocol ID
CFE/IF/28-20
Status last verified
Oct 2021
First submitted
8 Jun 2021
Last updated
18 Oct 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing black garlic in people with Hypercholesterolemia and Hypertension, run by Maria Pilar Zafrilla Rentero at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Impact on blood pressure (time frame: changes observed from baseline at day 0 compared to 12 weeks.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in